抗血管生成在NSCLC技术应用.pptVIP

下载本文档

8
0
约5.63万字
约 35页
2018-09-23 发布于江苏
举报
版权申诉

抗血管生成在NSCLC技术应用.ppt

此“医疗卫生”领域文档为创作者个人分享资料，不作为权威性指导和指引，仅供参考

1、本文档共35页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

* ATLAS – progression-free survival Miller VA, et al. J Clin Oncol 2009;27(Suppl 1):Abstract LBA8002 373 142 58 27 15 6 3 0 370 178 81 43 20 6 3 1 No. of patients at risk: Bev + placebo Bev + erlotinib Progression-free survival (months) 0 3 6 9 12 15 18 21 0.0 0.2 0.4 0.6 0.8 1.0 Proportion without event HR=0.722 (0.592–0.881) Log-rank p=0.0012 Bevacizumab + placebo (n=373) Bevacizumab + erlotinib (n=370) ATLAS – update on overall survival A 40% crossover rate (placebo patients to receive E once disease progressed) and underpowered design prevented trial from reaching significance for OS analysis 2-month OS benefit was observed in the Bv and E maintenance arm after occurrence of 57% events Biomarker analysis data of ATLAS study are expected soon Kabbinavar FF,?et al. J Clin Oncol 2010;28:15s (suppl; abstr 7526) Data cut-off Patients with events, n/N (%) Median OS (months) Bv + E vs Bv HR (95% CI) 18 July 2008 (pre-specified) 228/743 (31) 14.4 vs 13.3 0.92 (0.70–1.21) 19 June 2009 439/768* (57) 15.9 vs 13.9 0.90 (0.74–1.09) *25 patients were randomized after cut-off for main analysis of PFS ECOG5508: Phase III trial of BV, Pem, or BV+Pem as maintenance therapy in advanced NSCLC Carbo/pac/BV Q3w x 4 cycles Eligibility -BV eligible -non-squam -chemonaive -no CNS mets ?PI: S. Ramilingam; ; trial NCR Non-PD BV Induction Maintenance Pem BV+Pem Primary endpoint: OS Secondary: PFS S130 trial: Phase III trial of CP+Bv?Bv vs PemCarbo+Bv?Pem in first line NSCLC Eligibility -BV eligible -non-squam -chemonaive -treated brain mets Sponsor: Lilly; from ; trial NCR Carboplatin paclitaxel+BV (15mg/kg) q3w BV Pem Carboplatin pemetrexed Induction Maintenance Primary endpoint: PFS without grade 4 toxicity Secondary: PFS, ORR, DCR, toxicity Point Break: phase III trial of CP+Bv?Bv vs PemCarbo+Bv?Pem+BV (Sandler vs Patel) in first line NSCLC Eligibility -BV eligible -non-squam -chemonaive -treated brain mets ? PI J. Patel; Patel e